Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sandra Aliberti
Observed names:
Aliberti, Sandra,
S. Aliberti
Institution:
Candiolo Cancer Institute
Observed institutions:
Istituto Giannina Gaslini,
Azienda Ospedaliero Universitaria San Giovanni Battista,
Ospedale Civile Di Ivrea,
Istituto Ortopedico Rizzoli,
Candiolo Cancer Institute,
Fondazione IRCCS Istituto Nazionale dei Tumori,
University of Turin
show all 7
ORCID:
0000-0001-6990-9341
Observed ORCID:
0000-0001-6990-9341
OpenAlex ID:
A5077257491
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group
2018
·
Giovanni Grignani
, Lorenzo D'Ambrosio
, et al.
·
The Lancet Oncology
·
98
PDF
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
2017
·
Ymera Pignochino
, Federica Capozzi
, et al.
·
Molecular Cancer
·
75
PDF
Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour
2017
·
Lorenzo D'Ambrosio
, Erica Palesandro
, et al.
·
European Journal of Cancer
·
39
Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group
2023
·
Lorenzo D’Ambrosio
, Elena Fumagalli
, et al.
·
JAMA Network Open
·
15
PDF
LBA91 TOMAS2: A randomized phase II study from the Italian Sarcoma Group (ISG) of trabectedin plus olaparib (T+O) or trabectedin (T) in advanced, metastatic, or unresectable soft tissue sarcomas (STS) after failure of standard treatments
2023
·
L. D'Ambrosio
, A. Merlini
, et al.
·
Annals of Oncology
·
11
PDF
Trabectedin–olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group
2025
·
L. D’Ambrosio
, A. Merlini
, et al.
·
Annals of Oncology
·
10
Allogeneic Hemopoietic Stem Cell Transplantation in Solid Tumors
2005
·
F. Carnevale-Schianca
, A. Ricchiardi
, et al.
·
Transplantation Proceedings
·
10
TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group
2024
·
C. Fabbroni
, G. Grignani
, et al.
·
ESMO Open
·
9
PDF
Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing’s family tumours
2007
·
R. Luksch
, G. Grignani
, et al.
·
European Journal of Cancer
·
9
Erythrocyte macrocytosis is a rather common, apparently uneventful yet unexplained finding in GIST imatinib (I) chronic therapy
2005
·
S. Aliberti
, G. Grignani
, et al.
·
Journal of Clinical Oncology
·
9
Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions
2023
·
Alessandra Merlini
, Valeria Pavese
, et al.
·
Frontiers in Oncology
·
8
PDF
Positron-Emission Tomography in Cancer Therapy
2006
·
Sandra Aliberti
, Giovanni Grignani
, et al.
·
New England Journal of Medicine
·
8
1725MO IMMUNOSARC II master trial (phase II of sunitinib and nivolumab): Results from the clear cell sarcoma (CCS) cohort: A GEIS, ISG, and UCL study
2024
·
J. Martin-Broto
, E. Palmerini
, et al.
·
Annals of Oncology
·
5
A phase 1b trial with the combination of trabectedin and olaparib in relapsed patients (pts) with advanced and unresectable bone and soft tissue sarcomas (BSTS): An Italian Sarcoma Group (ISG) study.
2016
·
Giovanni Grignani
, Lorenzo D'Ambrosio
, et al.
·
Journal of Clinical Oncology
·
5
Response to Eribulin in a Patient with Metastatic Uterine Leiomyosarcoma: A Case Report
2020
·
Sandra Aliberti
, Sara Miano
, et al.
·
Future Oncology
·
3
PDF
IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort
2026
·
Javier Martin-Broto
, Sandra J. Strauss
, et al.
·
癌症:英文版
·
2
Performance and clinical utility of two targeted multigene panels for GIST molecular characterization
2025
·
Margherita Nannini
, Annalisa Astolfi
, et al.
·
Scientific Reports
·
2
PDF
Being the ultimate travel companion of a patient with uterine leiomyosarcoma
2022
·
Giovanni Grignani
, Alessandra Merlini
, et al.
·
Future Oncology
·
2
Tumor control with palliative external beam radiation therapy (EBRT) in advanced and unresectable osteosarcoma (OS) progressing after standard treatment.
2019
·
Francesco Tolomeo
, Marco Gatti
, et al.
·
Journal of Clinical Oncology
·
2
Imatinib mesylate (IM) therapy in elderly patients affected by advanced gastrointestinal stromal tumor (GIST).
2011
·
L. D'Ambrosio
, A. Ponzetti
, et al.
·
Journal of Clinical Oncology
·
2
Increase of creatine kinase value (CK) correlates with muscoloskeletal complaints (MSC) in GIST patients during imatinib therapy
2006
·
P. Allione
, G. Grignani
, et al.
·
Journal of Clinical Oncology
·
2
Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group network
2026
·
G.G. Baldi
, A.M. Frezza
, et al.
·
ESMO Open
·
1
2692MO Efficacy and safety of metronomic cyclophosphamide (MC) VS doxorubicin (DOXO) as first-line treatment in older patients (PTS) with advanced soft tissue sarcomas (STS): The METROPHOLYS trial
2025
·
A. Brunello
, M. Nannini
, et al.
·
Annals of Oncology
·
1
A risk-based individualized follow-up after complete surgery as an effective procedure to reduce the relapse (R) impact in GIST patients (pts).
2013
·
Erica Palesandro
, Danilo Galizia
, et al.
·
Journal of Clinical Oncology
·
1
Hypertension monitoring as a tool to predict congestive heart failure (CHF) during sunitinib (SU) therapy in GIST and renal cell carcinoma (RCC).
2011
·
D. Galizia
, C. Ortega
, et al.
·
Journal of Clinical Oncology
·
1
Show more works
View as search
Works count:
51
Citation count:
331
H-index:
9
I10-index:
7
Year
Topic
Type